- Enzalutamide, sold
under the
brand name
Xtandi, is a
nonsteroidal antiandrogen (NSAA)
medication which is used in the
treatment of
prostate cancer. It...
-
announced that the U.S. Food and Drug
Administration (FDA)
granted approval to
XTANDI (enzalutamide)
capsules for the
treatment of
patients with
metastatic castration-resistant...
- with Theravance.
Xospata (gilteritinib) – AXL
receptor tyrosine kinase Xtandi (enzalutamide) –
Prostate cancer –
marketed with Pfizer. The US Food and...
-
positive results from
phase 3 TALAPRO-2
trial of
Talzenna in
combination with
Xtandi in
patients with mCRPC". Pharmabiz.com.
October 11, 2024.
Retrieved March...
-
reduced risk of
seizures and
other central side effects.
Enzalutamide (
Xtandi):
Marketed for the
treatment of
prostate cancer. More
effective than the...
-
efficacious second-generation
nonsteroidal antiandrogens like
enzalutamide (
Xtandi),
apalutamide (Erleada), and
darolutamide (Nubeqa) also exist, but are very...
-
Pharma US, Inc. (August 2012). "Highlights of
Prescribing Information:
XTANDI (enzalutamide)
capsules for oral use" (PDF). U.S. Food and Drug Administration...
-
xorphanol (INN)
Xospata Xoterna Breezhaler Xphozah Xpovio Xromi Xtampza Er
Xtandi Xtoro Xtrelus Xulane Xultophy 100/3.6
Xultophy Xuriden Xydalba xylamidine...
-
Veterinary 1972
Veterinary 42,600
Enzalutamide Nonsteroidal AR
antagonist Xtandi Oral 2012
Available 328,000
Flutamide Nonsteroidal AR
antagonist Eulexin...
-
androgen response elements and
recruitment of coactivators.
Enzalutamide (
Xtandi)
Medivation Approved High
binding affinity to AR.
Unlike bicalutamide, it...
